Dr. Reddy's Q2 FY27 attributable profit falls 36% to Rs 9.25bn; revenue down 2%
Global Generics revenues from North America fell 23% to Rs 24,890m while India rose 17% and Emerging Markets 24%. Gross margin narrowed to 52.1% from 54.7%.
Every Earnings story, newest first. Each one is AI-generated and links its sources.
Search needs JavaScript. All stories are listed below, newest first.
Global Generics revenues from North America fell 23% to Rs 24,890m while India rose 17% and Emerging Markets 24%. Gross margin narrowed to 52.1% from 54.7%.
Adjusted operating income rose to SEK 14,693m from SEK 11,707m a year earlier. Reported operating income was SEK 14,354m, a 12.0% margin.
A SEK 24.6bn Gripen E order for Ukraine led large orders of SEK 52.1bn. Sales rose 30.6% organically and operating income (EBIT) rose 42% to SEK 1,945m.
North America's operating income excluding non-recurring items swung to SEK -90m from SEK 25m, while cost efficiency contributed SEK 1.4bn across the group.
Salvatore A. Abbate becomes President and Chief Executive Officer on 15 December 2026. Preliminary Q3 2026 revenue was $3.32bn, against $3.50bn a year earlier.
Provisions and expenses tied to what it called its fastest-ever originations growth pushed the student lender to a Q3 2026 loss; it now expects 2026 net charge-offs of $400m-$420m.
The New York lender blamed higher-for-longer interest rates; its Q3 2026 credit loss provision rose $58m from Q2, which it attributed mainly to higher rates, including on NYC rent-regulated loans.
Civil and commercial revenue dropped in fiscal Q2 2027 while national security work edged up; adjusted EPS rose 18.1% to $1.76.
The US heating, ventilation, air conditioning and electrical contractor reported Q3 2026 diluted EPS of $13.91, against $8.25 a year earlier, and operating cash flow of $1.01bn.
Revenue slipped to $990.5m. Online and Managed & Other Adjusted EBITDAR grew, and Boyd said Midwest & South grew after adjusting for a closure, a sale and higher property taxes.